UK Supreme Court rules against Actavis in Eli Lilly patent dispute


The UK Supreme Court has ruled that Actavis’s generic versions of cancer drug Alimta directly infringe patents owned by Eli Lilly, reversing two earlier decisions.

UK Supreme Court; Actavis; Eli Lilly; patent; Alimta; English Court of Appeal; pemetrexed